Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis

Table 1

Characteristic	Nab-paclitaxel plus gemcitabine (range)
Age (range)	66 (41–77)
≥70	17 (24%)
Sex
M	31 (44%)
F	39 (56%)
PS (Karnofsky)
100%	24 (34%)
80–90%	37 (53%)
60–70%	9 (13%)
Pancreatic primary location
Head	43 (61%)
Body/tail	27 (39%)
Site of metastasis
Lung	14 (20%)
Node	7 (10%)
Liver	47 (67%)
Peritoneum	15 (21%)
Bone	3 (4%)
Brain	1 (1%)
Number of metastatic sites
1	52 (74%)
≥2	17 (26%)
Biliary stent	16 (23%)
Median CA19.9	500 U/I (<1–61,564)
Previous surgery	16 (23%)
Previous adjuvant gemcitabine	10 (14%)